000 01411 a2200361 4500
005 20250515174054.0
264 0 _c20090715
008 200907s 0 0 eng d
022 _a1871-5303
024 7 _a10.2174/187153009788452426
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aFesten, Eleonora A M
245 0 0 _aInflammatory bowel disease and celiac disease: overlaps in the pathology and genetics, and their potential drug targets.
_h[electronic resource]
260 _bEndocrine, metabolic & immune disorders drug targets
_cJun 2009
300 _a199-218 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650 0 4 _aCeliac Disease
_xdrug therapy
650 0 4 _aHumans
650 0 4 _aImmunity, Innate
650 0 4 _aInflammatory Bowel Diseases
_xdrug therapy
650 0 4 _aInterleukin-17
_xphysiology
650 0 4 _aIntestinal Mucosa
_xmetabolism
650 0 4 _aNod2 Signaling Adaptor Protein
_xphysiology
650 0 4 _aPermeability
650 0 4 _aTh1 Cells
_ximmunology
650 0 4 _aTh2 Cells
_ximmunology
700 1 _aSzperl, Agata M
700 1 _aWeersma, Rinse K
700 1 _aWijmenga, Cisca
700 1 _aWapenaar, Martin C
773 0 _tEndocrine, metabolic & immune disorders drug targets
_gvol. 9
_gno. 2
_gp. 199-218
856 4 0 _uhttps://doi.org/10.2174/187153009788452426
_zAvailable from publisher's website
999 _c18939198
_d18939198